Analyzing MediWound (NASDAQ:MDWD) and Ocugen (NASDAQ:OCGN)

Ocugen (NASDAQ:OCGN) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Ocugen and MediWound, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1	0	4	0	2.60
MediWound	1	1	2	0	2.25

Ocugen currently has a consensus target price of $9.50, suggesting a potential upside of 831.37%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 151.72%. Given Ocugen’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocugen is more favorable than MediWound.

Profitability

This table compares Ocugen and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
MediWound	-170.10%	-47.24%	-24.27%

Risk & Volatility

Ocugen has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Insider and Institutional Ownership

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ocugen and MediWound”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41 million	78.43	-$67.85 million	($0.26)	-3.92
MediWound	$16.96 million	9.93	-$23.88 million	($1.80)	-7.28

MediWound has higher revenue and earnings than Ocugen. MediWound is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Summary

Ocugen beats MediWound on 8 of the 14 factors compared between the two stocks.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.